What is the price targets for Canopy Growth Stock?
The average twelve-month price target for Canopy Growth is $24.19 with a high price target of $55.00 and a low price target of $14.00. Learn more Do Wall Street analysts like Canopy Growth more than its competitors?
What is the upside from Canopy Growth's Stock?
According to analysts, Canopy Growth's stock has a predicted upside of 31.08% based on their 12-month price targets. What analysts cover Canopy Growth?
What does a hold rating mean for Canopy Growth's Stock?
A hold rating indicates that analysts believe investors should maintain any existing positions they have in CGC, but not buy additional shares or sell existing shares. View analyst ratings for Canopy Growth or view top-rated stocks. How has Canopy Growth's stock been impacted by COVID-19?
Should you hold Canopy Growth (CGC) stock?
The consensus among Wall Street analysts is that investors should "hold" Canopy Growth stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CGC, but not buy additional shares or sell existing shares. View analyst ratings for Canopy Growth or view top-rated stocks.
See more
Is canopy growth a Buy Sell or Hold?
Canopy Growth has received a consensus rating of Hold. The company's average rating score is 1.59, and is based on 2 buy ratings, 6 hold ratings, and 9 sell ratings.
Is canopy growth a buy Zacks?
The Zacks database contains over 10,000 stocks. All of those stocks are classified into three groups: Sector, M Industry and X Industry....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return1Strong Buy24.75%2Buy18.15%3Hold9.70%4Sell5.35%2 more rows
Is canopy stock a good buy?
Bottom line: Canopy Growth stock is not in a buy zone, so it isn't a buy right now. IBD's research shows investors would be better off looking for stocks with stronger fundamentals and that are closer to their highs. Check out IBD Stock Lists and other IBD content to find dozens of the best stocks to buy or watch.
What's the outlook for canopy growth?
Canopy Growth Corp (NASDAQ:CGC) The 16 analysts offering 12-month price forecasts for Canopy Growth Corp have a median target of 3.32, with a high estimate of 10.09 and a low estimate of 1.99. The median estimate represents a +28.58% increase from the last price of 2.58.
Will Canopy Growth ever pay dividends?
Does Canopy Growth Corporation pay a dividend? Canopy Growth Corporation does not currently pay a dividend and has no current plans to introduce one in the future.
What's happening to Canopy Growth?
Canopy Growth reported a 36% drop in revenue from Canadian recreational cannabis sales compared with the same quarter a year ago. Canopy Growth stock is plummeting after the marijuana company delivered financial results that fell short of expectations.
What stock should I buy now?
10 Stocks to Buy Now According to David Einhorn's Greenlight...Gulfport Energy Corporation (NASDAQ:GPOR) Greenlight Capital's Stake Value: $10,162,000. ... PLBY Group, Inc. (NASDAQ:PLBY) ... Civitas Resources Inc (NYSE:CIVI) ... TD SYNNEX Corporation (NYSE:SNX) ... International Seaways, Inc.
What is Canopy Growth's consensus rating and price target?
According to the issued ratings of 15 analysts in the last year, the consensus rating for Canopy Growth stock is Hold based on the current 8 sell r...
Do Wall Street analysts like Canopy Growth more than its competitors?
Analysts like Canopy Growth stock less than the stock of other Medical companies. The consensus rating for Canopy Growth is Hold while the average...
Do MarketBeat users like Canopy Growth more than its competitors?
MarketBeat users like Canopy Growth stock less than the stock of other Medical companies. 23.38% of MarketBeat users gave Canopy Growth an outperfo...
Is Canopy Growth being downgraded by Wall Street analysts?
Over the previous 90 days, Canopy Growth's stock had 3 downgrades by analysts.
Does Canopy Growth's stock price have much upside?
According to analysts, Canopy Growth's stock has a predicted upside of 17.52% based on their 12-month price targets.
What analysts cover Canopy Growth?
Canopy Growth has been rated by Alliance Global Partners , Barclays , Benchmark , BMO Capital Markets , Canaccord Genuity Group , Cfra, CIBC...
Is Canopy Growth stock a Buy, Sell or Hold?
Canopy Growth stock has received a consensus rating of sell. The average rating score is and is based on 1 buy ratings, 3 hold ratings, and 6 sell...
What was the 52-week low for Canopy Growth stock?
The low in the last 52 weeks of Canopy Growth stock was 3.62. According to the current price, Canopy Growth is 100.97% away from the 52-week low.
What was the 52-week high for Canopy Growth stock?
The high in the last 52 weeks of Canopy Growth stock was 26.36. According to the current price, Canopy Growth is 13.85% away from the 52-week high.
What are analysts forecasts for Canopy Growth stock?
The 10 analysts offering price forecasts for Canopy Growth have a median target of 15.35, with a high estimate of 55.00 and a low estimate of 3.50....
What is canopy growth?
Canopy Growth Corporation ("Canopy Growth" or "the Company") (TSX: WEED) (NASDAQ: CGC), a world-leading diversified cannabis, hemp, and cannabis device company, today announced two new offerings with the launch of Tweed Quickies and Ace Valley Pinners.
Who is the interim CEO of Canopy Growth?
Mike Lee, executive vice president and CFO and chief product officer Rade Kovacevic will depart the company on Dec. 31. "These decisions reflect management and the board's vision for building a best-in-class organization that is well-positioned to deliver long-term growth and shareholder value," Canopy Growth CEO Dav
Where is Canopy Growth located?
Analyst Report: Canopy Growth Corporation Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada , Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
What is canopy growth?
Canopy Growth Corp. engages in the production and sale of medical cannabis. The firm operates through the following segments: Global Cannabis and Other Consumer Products. The Global Cannabis segment encompasses the production, distribution and sale of a diverse range of cannabis and cannabinoid-based consumer products in Canada and internationally pursuant to applicable international and domestic legislation, regulations and permits. The Other Consumer Products segment encompasses the production, distribution and sale of consumer products by Storz & Bickel, This Works, BioSteel, and other ancillary revenue sources. It focuses on the treatment of chronic pain, seizures, muscle spasms, nausea, and loss of appetite. The company was founded by Bruce Linton on August 5, 2009 and is headquartered in Smith Falls, Canada.
What is the P/E ratio of canopy growth?
The P/E ratio of Canopy Growth is -4.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
What is the CGC symbol?
Canopy Growth trades on the NASDAQ under the ticker symbol "CGC."
Does canopy growth pay dividends?
Canopy Growth does not currently pay a dividend.
